R-Carphedon Enantiomer Synthesis for Enhanced Nootropic Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The pharmacological properties of N-carbamoylmethyl-4-aryl-2-pyrrolidinone (Carphedon) are not well understood due to the lack of data on its R- and S-enantiomers, leading to inadequate estimation of its pharmaceutical potential, as it is typically used as a racemic mixture with potentially different properties.
Innovation Solution
The development of methods to prepare pure R- and S-enantiomers of N-carbamoylmethyl-4-phenyl-2-pyrrolidinone, involving N-alkylation of 4(R)- or 4(S)-phenyl-2-pyrrolidinone with ethyl bromoacetate and subsequent transformation into carbamoyl function, revealing that R-Carphedon is more effective as an antidepressant, analgesic, and psycho-stimulant compared to the racemic and S-enantiomer forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If racemic Carphedon is used for pharmaceutical application, then it provides broad nootropic activity, but the pharmacological properties cannot be adequately estimated due to unknown effects of separate enantiomers
Solution Approach 1:
The racemic mixture is segmented into separate R- and S-enantiomers through asymmetric synthesis, allowing independent characterization of each enantiomer's pharmacological properties. This segmentation enables reliable estimation of pharmacological effects by studying pure enantiomers rather than mixed forms.
Solution Approach 2:
The synthesis method changes the stereochemical parameter by introducing chiral catalysts and asymmetric reaction conditions to produce enantiomerically pure compounds. This parameter change from racemic to pure enantiomeric forms enables detailed pharmacological characterization.
2Reliability
If GABA derivatives (Phenibut, Baclofen) are applied for stress relief, then nootropic activity is achieved, but drowsiness and depression occur as side effects
Solution Approach 1:
The R-enantiomer of Carphedon exhibits localized pharmacological activity with enhanced antidepressant and psycho-stimulating effects while avoiding the harmful side effects associated with GABA derivatives. The specific stereochemical configuration provides selective interaction with target receptors.
Solution Approach 2:
The invention replaces long-standing GABA derivatives with a novel pyrrolidinone structure that achieves similar or superior therapeutic effects without the associated side effects, effectively substituting one pharmaceutical class with a superior alternative.
3Ease of manufacture
If N-alkylation of 4(R/S)-phenyl-2-pyrrolidinone is performed to prepare Carphedon, then the compound can be produced, but separation and characterization of individual enantiomers is difficult
Solution Approach 1:
The asymmetric synthesis introduces chiral elements at early stages of the reaction sequence, establishing the correct stereochemistry before subsequent transformations. This preliminary establishment of chirality simplifies later separation and characterization steps.
Solution Approach 2:
Chiral catalysts and auxiliaries are introduced as intermediaries during the N-alkylation and subsequent transformations to control stereochemistry. These chiral intermediaries enable selective formation of R- or S-enantiomers during the synthetic sequence.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
R-Carphedon demonstrates enhanced antidepressant, muscle relaxant, and psycho-stimulating effects with lower side effects, outperforming racemic and S-Carphedon in various pharmacological tests, highlighting its higher therapeutic value.
Implementation Method 1
the preparation of R-Carphedon 4 the same as S-Carphedon 4a can be easily achieved by the means of the N-alkylation of available 4(R)-phenyl-2-pyrrolidinone (1) or 4(S)-phenyl-2-pyrrolidinone (1a) with ethyl bromoacetate (2) in the presence of a strong base
Implementation Method 2
by the following transformation of ethoxycarbonyl group in the intermediate 2-pyrrolidinones 3 and 3a into carbamoyl function by the treatment with ammonia
Data Source
AI summary
The invention relates to the R-enantiomer of N-carbamoylmethyl-4-phenyl-2-pyrrolidinone (R- Carphedon) of pharmacological value. The method of its preparation includes the N-alkylation of 4(R)-phenyl-2-pyrrolidinone with ethyl bromoacetate in the presence of a strong base and the treatment of intermediate N-ethoxycarbonylmethyl-4(R)-phenyl-2-pyrrolidinone with ammonia.